Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases.

Henit YanaiBella UngarUri KopylovTali Sharar FischlerIrit Avni BironJacob E OllechIdan GorenManar MatarTsachi Tsadok PeretsRaanan ShamirIris DotanShira AmirAmit Assa

Published in: Therapeutic advances in gastroenterology (2022)

Patients with IBD who switch from infliximab to adalimumab following an immunogenic failure are at increased risk for consecutive immunogenicity to adalimumab. IMM use after a switch prolongs drug retention.

Keyphrases

ulcerative colitis
rheumatoid arthritis
juvenile idiopathic arthritis
hidradenitis suppurativa
disease activity
emergency department
adverse drug